Abstract
We investigated the binding affinities of SM-7338 for penicillin-binding proteins (PBPs) and the morphological changes induced by it compared with those of imipenem. Both SM-7338 and imipenem had the highest binding affinities for PBP-2 of Escherichia coli, which were in good agreement with the primary morphological response of spherical cell formation. SM-7338 also showed high affinities for PBP-1A, -1Bs, and -3, and imipenem showed high affinities for PBP-1A and -1Bs but not for PBP-3. At 4-fold MIC, SM-7338 induced a indeterminate form, whereas imipenem did not. This may be due to the higher affinity of SM-7338 for PBP-3 compared to that of imipenem. Against Pseudomonas aeruginosa, SM-7338 had very high affinities for PBP-2 and -3, and imipenem had higher affinities for PBP-2 and -1A. SM-7338 induced this organism to filamentous cells at a concentration lower than its MIC, bulge cells at 2-fold MIC, and spherical cells at 4-fold MIC, while imipenem principally induced round cell formation at each concentration. These morphological differences in P. aeruginosa may be due to the differences in binding profiles to PBPs. We also studied the affinities for PBPs using radioactive SM-7338. The data obtained supported these results.
Citations
Apr 2, 2002·Expert Opinion on Investigational Drugs·Giovanni BonfiglioGiuseppe Nicoletti
Sep 29, 2005·Antimicrobial Agents and Chemotherapy·Yutaka UedaMakoto Sunagawa
Mar 7, 2008·Chemotherapy·Cağla Bozkurt Güzel, A Alev Gerçeker
Jun 12, 2009·Critical Reviews in Microbiology·M ShahidP M Hawkey
Mar 4, 2008·Expert Opinion on Pharmacotherapy·Jomy Joseph, Keith A Rodvold
Dec 28, 2018·The Journal of Antimicrobial Chemotherapy·Shazad MushtaqDavid M Livermore
May 1, 1995·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·H HanbergerM Nilsson
Oct 5, 2007·Expert Review of Anti-infective Therapy·Philip D Lister
Dec 24, 2008·Antimicrobial Agents and Chemotherapy·Tetsufumi KogaTakashi Fukuoka
Nov 11, 2015·Antimicrobial Agents and Chemotherapy·David M LivermoreNeil Woodford
Oct 6, 2000·Clinical Pharmacokinetics·J W MoutonA A Vinks
May 26, 2018·PLoS Pathogens·Edward GeisingerRalph R Isberg
Jan 30, 2007·Expert Opinion on Pharmacotherapy·Olaf BurkhardtTobias Welte
Apr 11, 2007·The Journal of Antibiotics·Ken EguchiNaomasa Gotoh
Oct 23, 2016·Cellular and Molecular Life Sciences : CMLS·T P Tim CushnieAndrew J Lamb
Sep 11, 1999·Bioorganic & Medicinal Chemistry·H AzamiM Murata
Nov 1, 1991·Antimicrobial Agents and Chemotherapy·M J PucciT J Dougherty
Sep 1, 1992·Antimicrobial Agents and Chemotherapy·G CornagliaG Satta
Feb 1, 1995·Antimicrobial Agents and Chemotherapy·J C Fung-TomcD P Bonner
Feb 1, 1995·Antimicrobial Agents and Chemotherapy·J C Fung-TomcD P Bonner
Apr 1, 1995·Antimicrobial Agents and Chemotherapy·G SattaR Fontana
Jun 1, 1991·Antimicrobial Agents and Chemotherapy·A RaimondiH Nikaido
Jan 1, 1991·Antimicrobial Agents and Chemotherapy·T MaejimaS Mitsuhashi
Apr 1, 1996·Antimicrobial Agents and Chemotherapy·R WhiteJ Bosso
Dec 1, 1993·Antimicrobial Agents and Chemotherapy·Y Sumita, M Fukasawa
Jun 12, 2019·ACS Chemical Biology·William J GodinezBrian Y Feng